Enanta Pharmaceuticals (ENTA)
Develops oral RSV antivirals and immunology drugs funded by AbbVie HCV royalties.
$12.08
vs last close−0.34 (−2.73%)
Something off on this page? Send us feedback.
Next report
Nov 16, 26
in 54 days
EPS estimate
−$0.77
Revenue estimate
$15.7M
Fiscal quarter
Q4 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$1.05−$1.06−$0.85−$0.87−$0.42−$0.45−$0.67Pending
Estimate−$1.16−$1.04−$1.25−$1.13−$0.54−$0.46−$0.51−$0.77
Surprise+9.5%−1.9%+32.0%+23.0%+22.2%+2.2%−31.5%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$17.0M$14.9M$18.3M$15.1M$18.6M$17.2M$14.4MPending
Estimate$17.2M$16.0M$16.0M$16.0M$15.9M$17.0M$16.8M$15.7M
Surprise−1.7%−6.5%+14.7%−5.3%+17.0%+0.8%−14.3%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Sep 2027 | −$0.53 | — | — |
| Jun 2027 | −$0.50 | — | — |
| Mar 2027 | −$0.43 | — | — |
| Dec 2026 | −$0.41 | — | — |
| Nov 2026 | −$0.77 | — | — |
| Aug 2026 | −$0.51 | −$0.67 | −31.5% |
| May 2026 | −$0.46 | −$0.45 | +2.2% |
| Feb 2026 | −$0.54 | −$0.42 | +22.2% |
| Nov 2025 | −$1.13 | −$0.87 | +23.0% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Sep 2027 | −$0.53 | — | — | $14.6M | — | — | — |
| Jun 2027 | −$0.50 | — | — | $15.2M | — | — | — |
| Mar 2027 | −$0.43 | — | — | $15.2M | — | — | — |
| Dec 2026 | −$0.41 | — | — | $16.2M | — | — | — |
| Nov 16, 2026 | −$0.77 | — | — | $15.7M | — | — | — |
| Aug 10, 2026 | −$0.51 | −$0.67 | −31.5% | $16.8M | $14.4M | −14.3% | −2.1% |
| May 11, 2026 | −$0.46 | −$0.45 | +2.2% | $17.0M | $17.2M | +0.8% | +0.8% |
| Feb 9, 2026 | −$0.54 | −$0.42 | +22.2% | $15.9M | $18.6M | +17.0% | +2.4% |
| Nov 17, 2025 | −$1.13 | −$0.87 | +23.0% | $16.0M | $15.1M | −5.3% | +6.3% |
| Aug 11, 2025 | |||||||
| May 12, 2025 | |||||||
| Feb 10, 2025 | |||||||
| Nov 25, 2024 | |||||||
| Aug 5, 2024 | |||||||
| May 6, 2024 | |||||||
| Feb 7, 2024 | |||||||
| Nov 20, 2023 | |||||||
| Aug 7, 2023 | |||||||
| May 8, 2023 | |||||||
| Feb 7, 2023 | |||||||
| Nov 21, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 9, 2022 | |||||||
| Feb 8, 2022 | |||||||
| Nov 22, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Feb 8, 2021 | |||||||
| Nov 23, 2020 | |||||||
| Aug 4, 2020 | |||||||
| May 6, 2020 | |||||||
| Feb 6, 2020 | |||||||
| Nov 21, 2019 | |||||||
| Aug 6, 2019 | |||||||
| May 7, 2019 | |||||||
| Feb 6, 2019 | |||||||
| Nov 26, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 8, 2018 | |||||||
| Feb 7, 2018 | |||||||
| Nov 20, 2017 | |||||||
| Aug 7, 2017 | |||||||
| May 8, 2017 | |||||||
| Feb 8, 2017 | |||||||
| Nov 21, 2016 | |||||||
| Aug 8, 2016 | |||||||
| May 9, 2016 | |||||||
| Feb 8, 2016 | |||||||
| Nov 23, 2015 | |||||||
| Aug 6, 2015 |